Barrett's Esophagus Clinical Trial
Official title:
High Resolution Magnifying Endoscopy and Contrast Enhanced Imaging Versus Standard White Light Endoscopy for the Detection of Dysplasia in Barrett's Esophagus. A Prospective Blinded Cross-over Study.
The purpose of this study is to determine whether High Resolution Magnification Endoscopy (HRME) and Computed Virtual Chromoendoscopy (CVC) with targeted biopsies is superior to conventional white light endoscopy (WLE) with 4 quadrant biopsies of the metaplastic epithelium every 1-2 cm (Seattle Protocol) for detection of pre-malignant lesions in patients with Barrett's Esophagus (BE).
BE is a metaplastic mucosal transformation adjacent to the esophagogastric junction, due to
chronic reflux of gastric juices, Gastro Esophageal Reflux Disease (GERD). The continuous
esophageal exposure of acid- and/or bile- containing fluids leads, untreated, to chronic
esophagitis. In certain patients a mucosal transformation takes place. The epithelium in the
distal part of esophagus is transferred from squamous into a more intestinal-like mucosa,
called Specialized Intestinal Metaplasia (SIM).Patients with BE is believed to run a higher
risk of developing esophageal adenocarcinoma (EAC).
EAC is a rare condition in the western society, but the prevalence is rising compared with
other malignancies, and a substantial increase has been seen during the last four decades.
The pathogenesis of cancer development is believed to be that SIM in some patients can
undergo dysplastic transformation, from low to high grade, and from high grade dysplasia
(HGD) develop into AC. Advanced EAC is associated to a poor prognosis whereas HGD or
carcinoma in situ may be treated endoscopically with a favorable outcome.
The need for surveillance endoscopy in order to discover early cancer lesions available to
curable treatment is up against cost effectiveness and evidence level regarding screening.
The conventional endoscopic (CE) surveillance algorithm for BE is standard WLE and 4
quadrant biopsies of the metaplastic epithelium every 1-2 cm above the esophagogastric
junction. The development of advanced endoscopic techniques have made it possible to
distinguish minimal polypoid lesions but also the microvasculature and pit-pattern
structures that in certain grading systems have been associated to presence of dysplasia.
Attempts have been made in exploring the benefits of advanced endoscopic technologies
against standard WLE. Feasibility-studies suggests that the new techniques improves the
biopsy-yield for dysplasia, however only a limited number of prospective studies exist.
Study aim: To determine whether HRME and CVC with targeted biopsies is superior to
conventional WLE with 4 quadrant biopsies of the metaplastic epithelium every 1-2 cm
(Seattle Protocol) for detection of pre-malignant lesions in patients with BE.
Primary endpoint: Incidence of detected dysplasia by each endoscopic technique. Secondary
endpoints: 1.The yield of low- and/or high-grade dysplasia by each endoscopic technique.
2.The number of biopsies taken and the duration of the different endoscopic techniques.
3.The endoscopic prediction capability of present dysplasia compared to histopathology for
HRME.
Statistical power: Based on the primary endpoint, the amount of dysplasia in a
Barrett-population is approximately 10%. We calculated a raise in positive yield with using
advanced endoscopy to 8%. At p<0,05 and a power of 80% the need for 105 patients.
Setting: Tertiary referral high volume endoscopy center at Sahlgrenska University Hospital,
Sweden.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02864043 -
Barrett's Dysplasia Detection Pilot Trial Using the NvisionVLE® Imaging System
|
N/A | |
Recruiting |
NCT02018367 -
Accuracy, Yield and Clinical Impact of a Low-Cost HRME in the Early Diagnosis of Esophageal Adenocarcinoma
|
Phase 2 | |
Terminated |
NCT01572987 -
Endoscopic Resection or Ablation for Patients With Dysplasia or Cancer Requiring Treatment of Barrett's Esophagus
|
N/A | |
Terminated |
NCT01976351 -
Imaging Enhanced Endoscopy for the Screening of Barrett's Esophagus
|
N/A | |
Terminated |
NCT00526786 -
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
|
Phase 4 | |
Completed |
NCT01401699 -
Optical Coherence Tomography (OCT) Based Screening of Esophagus and Gastroesophageal Junction
|
N/A | |
Completed |
NCT02106910 -
Non-Endoscopic Surveillance for Barrett's Esophagus Following Ablative Therapy
|
N/A | |
Suspended |
NCT01580631 -
Narrow Band Imaging Project on Barrett's Esophagus
|
||
Completed |
NCT01439633 -
Optical Frequency Domain Imaging (OFDI) Surveillance and Image Guided Biopsy of the Esophagus
|
N/A | |
Completed |
NCT02879721 -
Expression and Function of the Renin-Angiotensin System in the Esophagus
|
Phase 0 | |
Completed |
NCT01439594 -
Optical Frequency Domain Imaging (OFDI) Assessment in Radiofrequency Ablation
|
N/A | |
Completed |
NCT01281618 -
Influence of Acid Reflux on Stromal Epithelial Interaction in Barrett's Esophagus
|
N/A | |
Completed |
NCT00586872 -
Endoscopic Mucosal Resection (EMR) in Barrett's Esophagus
|
||
Completed |
NCT00844077 -
Preliminary Longitudinal Validation of Biomarkers Predictive of Barrett's Esophagus
|
N/A | |
Completed |
NCT00588575 -
Ramanspectroscopy in Barrett's Esophagus
|
||
Recruiting |
NCT00288119 -
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
|
||
Completed |
NCT03813381 -
CAlorie and Protein REstriction PROgram in Barrett's Esophagus Patients (CARE-PRO).
|
N/A | |
Completed |
NCT02579460 -
Reflux-Induced Oxidative Stress in Barrett's Esophagus: Response, Repair, and Epithelial-Mesenchymal-Transition
|
N/A | |
Not yet recruiting |
NCT02033070 -
Patient Registry: Radio Frequency Ablation of Barrett's Esophagus Using HALO System
|
N/A | |
Completed |
NCT01961778 -
Comparison of Treatments for Barrett's Esophagus With High-Grade Dysplasia/Early Adenocarcinoma
|
N/A |